PolyNovo names new CEO


By Dylan Bushell-Embling
Monday, 16 February, 2015

PolyNovo (ASX:PNV) has appointed 20-year health sciences veteran Paul Brennan as its new CEO, effective immediately.

Brennan has extensive experience in health product development, market analysis regulatory pathways, competitor analysis and other aspects of the commercialisation process.

As CEO, Brennan will receive a remuneration package including a $270,000 salary and both long- and soft-term incentives.

Due to the appointment, former joint managing directors Philip Powell and David McQuillan have reverted to independent non-executive directors.

PolyNovo has also named Ivy Cheng as the company’s first regulatory affairs and clinical compliance manager.

Cheng will assume her new role in mid-March and help the company prepare to undertake trials to facilitate registration of its products in areas including wound and burns treatment.

Last year, PolyNovo secured both a CE Mark and US FDA 510(k) clearance for topical negative pressure (TNP) foam dressing NovoPore.

PolyNovo’s former parent company, Calzada, changed its name to PolyNovo and divested its subsidiary Metabolic Pharmaceuticals last year as part of a restructuring process.

Polynovo (ASX:PNV) shares were trading 2.27% higher at $0.09 as of around 1.30 pm on Monday.

Related News

High-potency cannabis use leaves a unique mark on DNA

Frequent users of high-potency cannabis have changes in genes related to mitochondrial and immune...

Scaffold-based method for culturing antitumour bacteria

Bacteria-based cancer therapy represents an exciting new treatment option — but in order to...

mpox vaccine appears safe and effective in adolescents

Interim analysis of an mpox vaccine trial has found the vaccine is safe in adolescents and...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd